
CLAIMS

What is claimed is:

1. A compound of structural Formula I



$\bullet (M)_a \bullet (H_2O)_b$

(I)

or a polymorph thereof, wherein:

a is a fractional or whole number between about 0.5 and 3.5, inclusive;

b is a fractional or whole number between about 0 and 10, inclusive; and

M is selected from hydrochloric acid, phosphoric acid, and acetic acid.

2. The compound as recited in claim 1, wherein a is about 1.0.

3. The compound of claim 2, wherein M is hydrochloric acid.

4. The compound of claim 3, characterized by the presence of four or more peaks with d-spacings of about 14.1, 12.9, 10.1, 8.8, 8.5, 6.5, 5.5, 5.1, 4.8, and 4.4 Å.

5. The compound of claim 4, characterized by the presence of six or more peaks with d-spacings of about 14.1, 12.9, 10.1, 8.8, 8.5, 6.5, 5.5, 5.1, 4.8, and 4.4 Å.

6. The compound of claim 5, characterized by the presence of eight or more peaks with d-spacings of about 14.1, 12.9, 10.1, 8.8, 8.5, 6.5, 5.5, 5.1, 4.8, and 4.4 Å.

7. The compound of claim 3, characterized by the presence of four or more peaks with d-spacings of about 16.5, 14.5, 10.5, 9.1, 8.3, 7.8, 7.6, 5.2, 4.7, and 4.1 Å.

8. The compound of claim 7, characterized by the presence of six or more peaks with d-spacings of about 16.5, 14.5, 10.5, 9.1, 8.3, 7.8, 7.6, 5.2, 4.7, and 4.1 Å.

9. The compound of claim 8, characterized by the presence of eight or more peaks with d-spacings of about 16.5, 14.5, 10.5, 9.1, 8.3, 7.8, 7.6, 5.2, 4.7, and 4.1 Å.

10. The compound of claim 2, wherein M is acetic acid.

11. The compound of claim 10, characterized by the presence of four or more peaks with d-spacings of about 14.6, 10.6, 9.4, 8.0, 7.4, 6.6, 5.1, 4.3, 4.0 and 3.9 Å.

12. The compound of claim 11, characterized by the presence of six or more peaks with d-spacings of about 14.6, 10.6, 9.4, 8.0, 7.4, 6.6, 5.1, 4.3, 4.0 and 3.9 Å.

13. The compound of claim 12, characterized by the presence of eight or more peaks with d-spacings of about 14.6, 10.6, 9.4, 8.0, 7.4, 6.6, 5.1, 4.3, 4.0 and 3.9 Å.

14. A compound as recited in any of claims 1-13 for use as a medicament.

15. A compound as recited in any of claims 1-13 for use in the treatment of a disease.

16. A compound as recited in any of claims 1-13 for use in the manufacture of a medicament for the prevention or treatment of a disease.

17. A pharmaceutical composition comprising a compound as recited in any of claims 1-13 together with a pharmaceutically acceptable carrier.

18. A method of inhibition of microbial protein synthesis comprising contacting bacteria with a compound as recited in any of claims 1-13.

19. The method as recited in claim 18, wherein the microbe is a bacterium.

20. The method as recited in claim 18, wherein the microbe is a protozoan.

21. Use of a therapeutically effective amount of the compound as recited in any of claims 1-13 in the manufacture of a medicament for treating ~~A method of treatment of~~ an infectious disease in ~~comprising the administration of a therapeutically effective amount of a compound as recited in any of claims 1-13 to~~ a patient in need thereof.

~~22.~~ Use of a therapeutically effective amount of the compound as recited in any of claims 1-13 in the manufacture of a medicament for treating ~~A method of treatment of~~ an infectious disease, by co-administration with another therapeutic agent ~~comprising the administration of:~~

~~23. a therapeutically effective amount of a compound as recited in any of claims 1-13; and~~

~~24.~~22. ~~another therapeutic agent~~.

~~25.~~23. The ~~method~~ use as recited in either one of claims 21 and 22 wherein said infectious disease is anthrax.

~~26.~~24. The ~~method~~ use as recited in either one of claims 21 and 22 wherein said infectious disease is malaria.

~~27.~~25. The ~~method~~ use as recited in either one of claims 21 and 22 wherein said infectious disease is caused by a bacterium.

~~28.~~26. The ~~method~~ use as recited in any of claims 21 and 22 wherein said infectious disease is caused by a protozoan.

~~29.~~27. Use of a therapeutically effective amount of the compound as recited in any of claims 1-13 in the manufacture of a medicament for ~~A method for~~ achieving an effect in a patient ~~comprising the administration of a therapeutically effective amount of the compound as recited in any of claims 1-13 to a patient~~, wherein the effect is chosen from:

reducing microbial level(s);

increasing the rate of microbial killing;

decreasing the minimal dose for cure (e.g., reduction of the level of microbia to an undetectable level); and

decreasing the duration of time required for cure (e.g., reduction of the level of microbia to an undetectable level).

~~30.~~28. The ~~method~~ use as recited in claim 27, wherein the microbe is a bacterium.

~~31.~~29. The ~~method~~ use as recited in claim 27, wherein the microbe is a protozoan.

~~32.~~30. The ~~method~~ use as recited in any of claims 19, 25, and 28, wherein the bacterium is chosen from *Bacteroides*, including, for example, *B. tectum*; *Corynebacterium*; *Chlamydia*, including, for example, *C. pneumoniae* and *C.*

trachomatis; *Eikenella*, including, for example, *E. corrodens*; *Enterobacteriaceae*; *Fusobacterium*, including, for example, *F. nucleatum*; *Haemophilus*, including, for example, *H. influenzae*; *Leigonella*, including, for example, *L. pneumophila; Moraxella*, including, for example, *M. catarrhalis*; *Mycobacterium*, including, for example, *M. avium, M. intracellulare*, *M. chimaera*, *M. kansasii*, *M. malmoense*, *M. xenopi*, *M.abscessus*, *M. fortuitum* complex, and *M. chelonae*; *Mycoplasma*, including, for example, *M. hominis*, *M. genitalium*, and *M. pneumoniae*; *Neisseria*, including, for example, *N. gonorrhoeae*; *Pasturella*, including, for example, *P. septica* and *P. multocida*; *Peptostreptococcus*, including, for example, *P. magnus* and *P. micros*; *Prevotella*, including, for example, *P. melaninogenica* and *P. heparinolytica*; *Porphyromonas*; *Propionibacterium*; *Staphylococcus*, including, for example, *S. aureus*; *Streptococcus*, including, for example, *S. pneumoniae*; *Ureaplasma*, including, for example, *U. urealyticum* and *U. parvum*; and *Veillonella*.

~~33.~~31. The ~~method~~ use as recited in as recited in either one of claims 20, 26, and 29, wherein the protozoan is chosen from *Cryptosporidium*; *Coccidia*; *Plasmodium*; *Toxoplasma*; *Babesia*; and *Neospora*.

~~34.~~32. The ~~method~~ use as recited in claim 31, wherein the protozoan is *Toxoplasma gondii*.

~~35.~~33. The ~~method~~ use as recited in claim 31, wherein the protozoan is a *Plasmodium* species.

~~36.~~34. The ~~method~~ use as recited in claim 33, wherein the *Plasmodium* is chosen from *P. falciparum*, *P. vivax*, *P. ovale*, *P. malariae*, and *P. knowlesi*.

~~37.~~35. The ~~method~~ use as recited in claim 34, wherein the *Plasmodium* is *P. falciparum*.